| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CareDx, Inc.$28.51
-0.1 (-0.34%)
F 18Pipeline Score Diagnostics · Commercial
Market Cap
1.12 B
EPS
-0.15
P/E Ratio
-
Value Trade
15.49 M
SEC Financials
Q1 2026Dilution Risk
Revenue
117.70 M
R&D Expenses
21.42 M
Operating CF
4.33 M
Total Assets
411.06 M
Total Liabilities
97.53 M
Equity
313.54 M
D/E Ratio
12,345
8.15 %
Week
2.32 %
1 Month
9.69 %
3 Month
36.99 %
6 Month
-70.77 %
5 Year
127.68 %
All Time
Cash Data
Cash Position
187.18 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 28, 2026
Overview
Volume
665.78 K
52 Week Range
10.96 - 23.24
% held by Insiders
9.6 %
% held by Institutions
95.78 %
Enterprise Value
954.72 M
Total Shares
51.67 M
Short %
16.65 %
Float Shares
50.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CareDx, Inc.
3Total events
1Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
Drug Pipeline Intelligence
F18
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 17%
Micro Cap (rank 757 of 911)
Percentile RankCareDx, Inc. has significant pipeline risk (18/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AlloHeme | acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) | — | 2026-02-12 | sensitivity: 85%; specificity: 92%; negative predictive value: 95%; positive predictive value: 79%; area under curve: 0.89; median detection lead time: 41 days; relapse risk increase: 12-fold higher Read More | CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy Read More | |
AlloHeme | acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) | — | 2026-02-12 | sensitivity: 85%; specificity: 92%; negative predictive value: 95%; positive predictive value: 79%; area under curve: 0.89; median detection lead time: 41 days; relapse risk increase: 12-fold higher Read More | CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy Read More | |
AlloHeme | acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) | — | 2026-02-12 | sensitivity: 85%; specificity: 92%; negative predictive value: 95%; positive predictive value: 79%; area under curve: 0.89; median detection lead time: 41 days; relapse risk increase: 12-fold higher Read More | CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CDNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CDNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CDNACareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx has successfully completed the acquisition of Naveris, a strategic move aimed at enhancing its position in the specialty oncology market. This acquisition is expected to drive growth and expand CareDx's offerings in a high-demand area. The integration of Naveris will further solidify CareDx's leadership in oncology.
Read more →CDNAEurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has finalized the acquisition of CareDx's Lab Products division, enhancing its capabilities in in-vitro diagnostics for transplantation. This strategic move aims to create a leading provider of genomic typing and transplantation diagnostics. The integration will expand product offerings and improve operational efficiencies across key markets.
Read more →CDNACareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx has announced the completion of the sale of its lab products business to Eurobio Scientific. This strategic move is part of CareDx's ongoing efforts to streamline operations and focus on its core competencies. The transaction is expected to enhance both companies' market positions in the diagnostics sector.
Read more →CDNA▲ +11.5%on this news
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
CareDx showcased its precision medicine diagnostics at the 2026 American Transplant Congress, presenting over 30 abstracts and 9 oral presentations. This event highlights the company's commitment to advancing transplant medicine through innovative diagnostic solutions. The presentations are expected to contribute valuable insights into the field.
Read more →CDNACareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
CareDx has announced the publication of its second KOAR analysis in the Journal of the American Society of Nephrology. This publication highlights the ongoing research and findings related to kidney transplant management. Details about the analysis and its implications for patient care were not disclosed in the announcement.
Read more →CDNACareDx to Participate in Upcoming June 2026 Investor Conferences
CareDx, Inc. (CDNA) has announced its participation in investor conferences scheduled for June 2026. The company will host a fireside chat on June 8, 2026, at 1:20 PM ET. Webcasts of the presentations will be accessible via their investor relations website, highlighting their commitment to transparency and investor engagement.
Read more →CDNACareDx to Participate in Upcoming Investor Conferences
CareDx has announced its participation in upcoming investor conferences. The details regarding the specific conferences and the nature of their participation were not disclosed in the article. This move is likely aimed at enhancing investor relations and visibility in the market.
Read more →CDNACareDx Announces Dismissal of 2021 Qui Tam Suit
CareDx has announced the dismissal of a qui tam lawsuit filed in 2021. This legal victory may positively impact the company's reputation and investor confidence. The dismissal signifies a resolution to the legal challenges faced by CareDx, allowing the company to focus on its core operations.
Read more →CDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
CareDx, Inc. has announced the award of inducement grants to 23 new employees, totaling 63,856 restricted stock units (RSUs). These grants are part of the company's 2019 and 2025 Inducement Equity Incentive Plans, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting employee retention.
Read more →CDNACareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx has announced a definitive agreement to acquire Naveris, a leader in viral-mediated cancer monitoring. The acquisition, valued at $160 million upfront and additional milestone payments, aims to enhance CareDx's precision medicine services. Naveris's liquid biopsy platform is recognized for its accuracy in detecting HPV-driven cancers. The transaction is expected to close in Q3 2026, pending customary conditions.
Read more →CDNACareDx Announces First Quarter 2026 Financial Results
CareDx, Inc. reported strong financial results for Q1 2026, with revenues reaching $118 million, a 39% increase from the previous year. The company saw significant growth in testing services, which rose by 48%, and achieved a GAAP net income of $3 million, a turnaround from a loss in Q1 2025. CareDx also announced a strategic divestiture of its Lab Products business and launched an AI-driven clinical data platform.
Read more →CDNACareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting
CareDx, Inc. announced its participation in the ISHLT 2026 Annual Meeting, where it will present more than 50 abstracts, including 16 oral presentations. This event, scheduled for April 22-25 in Toronto, Canada, emphasizes CareDx's commitment to advancing transplant medicine through innovative research and clinical applications.
Read more →CDNACareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
CareDx has introduced AlloSeq Nano at EFI 2026, enhancing its HLA typing portfolio through long-read sequencing technology. This development aims to improve the accuracy and efficiency of HLA typing, which is crucial for organ transplantation. The introduction of this new product reflects CareDx's commitment to advancing transplant diagnostics.
Read more →CDNA▲ +27.6%on this newsshared move
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results
CareDx has announced a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million. This strategic move aims to enhance CareDx's focus on its core precision medicine testing services, which have shown significant revenue growth. The transaction is expected to close by the end of the third quarter of 2026, pending regulatory approval.
Read more →CDNACareDx to Report First Quarter 2026 Financial Results on April 28, 2026
CareDx, Inc. has announced that it will report its financial results for the first quarter of 2026 on April 28, 2026. The report will be released after market close, followed by a webcast and conference call at 1:30 p.m. PT. The company specializes in precision medicine for transplant patients.
Read more →CDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. has announced the award of inducement grants to 35 new employees, totaling 82,137 restricted stock units (RSUs). These grants are part of the company's equity incentive plans and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, incentivizing employee retention and commitment.
Read more →CDNACareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
CareDx, Inc. will participate in the Raymond James 47th Annual Institutional Investors Conference on March 3, 2026. The company is known for its precision medicine solutions aimed at enhancing outcomes for transplant patients. CareDx offers a range of services including non-invasive testing and digital health technologies.
Read more →CDNACareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
CareDx has announced the clinical validation of AlloHeme, an AI-powered NGS test for monitoring relapse in AML and MDS patients post-transplant. The test demonstrated high sensitivity and specificity, identifying relapse significantly earlier than traditional methods. This innovation marks a strategic expansion for CareDx into the cell therapy market, with a planned launch starting in 2026.
Read more →CDNACareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
CareDx, Inc. will announce its financial results for Q4 and the full year 2025 on February 24, 2026. The announcement will be followed by a webcast and conference call at 1:30 p.m. PT. CareDx specializes in precision medicine solutions for transplant patients and caregivers.
Read more →CDNA▼ -8.2%on this news
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. will present pivotal clinical validation data for AlloHeme at the 2026 Tandem Meetings. The ACROBAT study evaluates AlloHeme's effectiveness in detecting cancer relapse post-transplantation. The study includes patients with AML and MDS across 11 centers. An investor webcast is scheduled for February 12, 2025, to discuss findings and launch timelines.
Read more →CDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 26, 2025
CareDx, Inc. announced the award of inducement grants to 39 new employees, totaling 80,425 restricted stock units (RSUs). These grants are part of the company's 2025 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting employee retention and commitment.
Read more →CDNAUNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAYSEN STEVENSON, and CHRISTIAN JACOBSEN, Derivatively on Behalf of CareDx, Inc., Plaintiffs, v. GEORGE BICKERSTAFF, FRED COHEN, CHRISTINE COU
CareDx, Inc. is involved in shareholder derivative litigation regarding alleged breaches of fiduciary duties by several officers and directors. Recent developments include a proposed settlement that, if approved, would prevent current shareholders from contesting the settlement. The allegations involve claims of materially false statements about testing services and a lack of adequate oversight by the defendants. A court hearing is scheduled to further discuss the settlement details and its implications for the shareholders.
Read more →CDNACareDx Announces Repurchase of 5% of Outstanding Shares Board of Directors Authorizes New $50 Million Share Repurchase Program BRISBANE, Calif. - CareDx, Inc. (Nasdaq: CDNA), The Transplant Company a leading precision me
CareDx, Inc. (Nasdaq: CDNA) has announced the completion of a $50 million share repurchase, representing approximately 5% of its outstanding shares. This decision follows a successful first quarter where the company achieved $84.7 million in revenue, marking an 18% increase year-over-year. Additionally, CareDx's Board of Directors has authorized a new share repurchase program of up to $50 million over the next 24 months. The company expressed confidence in its growth trajectory and long-term financial goals, aiming for $500 million in revenue by 2027.
Read more →CDNA▲ +6.1%on this news
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million BRISBANE, Calif. (BU
CareDx, Inc. has reported preliminary results indicating a 30% increase in fourth quarter revenue year-over-year, projecting full year 2024 revenues between $332 million and $333 million. The company also mentions continuous growth in testing services, led by kidney surveillance testing, and significant expansion in its sales and marketing teams. Looking ahead, CareDx aims for $500 million in revenue and 20% adjusted EBITDA by 2027, with a more detailed report on the financial results expected in February 2025. However, these projections are subject to potential adjustments based on the completion of annual audits and market uncertainties.
Read more →CDNA▼ -15.8%on this news
CareDx Reports Preliminary Financial Results for Third Quarter 2024 Third Quarter 2024 Financial Results to be Reported on
CareDx, Inc. announced preliminary financial results for the third quarter of 2024, highlighting growth across all lines of business. CEO John W. Hanna expressed optimism about the company's performance leading into the fourth quarter. Official financial results are set to be reported on November 4, 2024. CareDx is recognized for its specialized healthcare solutions for transplant patients and continues to emphasize its strategic focus on precision medicine.
Read more →CDNAFinal Press Release For Newswire Issue, Thursday, 9/12/24. 7:01 am ET. CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer CareDx Announces Addition of Operational and Commerci
CareDx has announced the appointment of Keith Kennedy as Chief Operating Officer and Jessica Meng as Chief Commercial Officer, aimed at enhancing its operational and commercial strategies. The company plans to reveal its long-term growth strategy at an upcoming Investor Day in October 2024. Kennedy and Meng both bring significant experience in healthcare and biopharma, potentially positioning CareDx for enhanced operational excellence and market growth.
Read more →CDNACareDx Appoints John W. Hanna as its New President and Chief Executive Officer BRISBANE, CA
CareDx, Inc. has appointed John W. Hanna as its new President and Chief Executive Officer, taking effect on April 15, 2024. Hanna, who has over two decades of experience in molecular diagnostics, is expected to lead the company in propelling growth and enhancing patient outcomes for transplant patients. His previous roles include executive leadership at Apton Biosystems and Veracyte, showcasing a strong background in new technology development. The Board of Directors expresses full confidence in Hanna's capabilities and vision for the company's future.
Read more →CDNACareDx Appoints Bryan Riggsbee to Its Board of Directors
CareDx, Inc. has appointed Bryan Riggsbee to its Board of Directors, effective March 11, 2024. Riggsbee brings extensive experience in finance from his previous roles, including serving as CFO at Myriad Genetics and a decade at Laboratory Corporation of America. He will chair the Audit and Finance Committee, succeeding George Bickerstaff. Riggsbee expressed enthusiasm for contributing to CareDx's initiatives aimed at improving outcomes for transplant patients.
Read more →CDNACareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023 BRISBANE, Calif. (BUSINESS WIRE)
CareDx, Inc. has reported preliminary revenue results indicating a decline in financial performance for the fourth quarter and full year of 2023. The company anticipates fourth-quarter revenue between $65 million and $66 million, marking a 3% decrease from the previous quarter and a 13% drop in overall annual revenue compared to 2022. Despite these challenges, CareDx reported growth in its Patient and Digital Solutions and Product revenues. The company plans to report complete financial results and guidance for 2024 in an upcoming earnings call.
Read more →CDNACareDx Announces CEO Transition Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance
CareDx announced a leadership transition as Dr. Reginald Seeto steps down as CEO, effective November 1, 2023, to become Senior Advisor. The company has established an Office of the CEO while searching for a permanent successor. Despite the CEO change, CareDx raised its revenue guidance for 2023 to between $274 million and $278 million, reflecting strong operational performance. More details are expected to be shared during the upcoming earnings call on November 8, 2023.
Read more →CDNACareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx and Miromatrix have entered an exclusive partnership to develop innovative bioengineered organs for transplantation. CareDx will provide dd-cfDNA testing services to assess organ transplant rejection, essential for Miromatrix's clinical studies. The collaboration aims to tackle the critical organ supply shortage faced by patients awaiting transplants in the U.S. Both companies emphasize their commitment to revolutionizing organ transplantation through advanced technology.
Read more →CDNA▲ +5.6%on this news· ran to +24% by day 3
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
CareDx, Inc. reported preliminary revenue results for the fourth quarter and full year 2022, highlighting a revenue increase of about 4% in Q4 compared to the previous year and an 8% increase for the year overall. Testing services revenue for Q4 is projected to be between $64.9 million and $65.2 million, down from the previous year's $68.6 million. The CEO expressed optimism for the upcoming year, anticipating continued growth and adjusted EBITDA profitability by the first half of 2023. Full financial results will be disclosed in February 2023 during an earnings call.
Read more →CDNACareDx, Inc. Investor News: Robbins LLP is Investigating CareDx, Inc. (CDNA) on Behalf of Shareholders
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating CareDx, Inc. (NASDAQ: CDNA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws by engaging in improper schemes to i
Read more →CDNA▲ +7.1%on this news
CAREDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
NEW ORLEANS, July 19, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (Nasd
Read more →CDNA▲ +6.6%on this newsshared move
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors With Losses in Excess of $100,000 of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx Inc. (NASDAQ: CDNA)
Did you lose money on investments in CareDx? If so, please visit CareDx, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nation
Read more →CDNACAREDX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
NEW ORLEANS, July 12, 2022 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit
Read more →CDNACareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx Inc. (NASDAQ: CDNA)
Did you lose money on investments in CareDx? If so, please visit CareDx, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nation
Read more →CDNACareDx, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CareDx, Inc. (NASDAQ: CDNA) investors that a class action filed on behalf of investors. CareDx investors that los
Read more →CDNA▼ -7.9%on this news· ran to -22% by day 3
CareDx Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at CareDx
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA), a diagnostics company that provides services and products to the organ transplant
Read more →CDNACareDx Class Action Complaint Filed: Johnson Fistel, Globally Recognized Law Firm Encourages Shareholders to Submit Their Losses
SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of CareDx, Inc. (NASDAQ: CDNA). The class action is on behalf of shareholders who purchased CareDx securities bet
Read more →CDNACareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation
SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNACareDx Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 23, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CareDx, Inc ("CareDx" or the "Company") (NASDAQ: CDNA) investors that a class action filed on behalf of investors
Read more →CDNA▼ -8%on this news
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNA▼ -6.2%on this news
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNA▼ -7.1%on this news· ran to -32% by day 3
CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced
Read more →CDNA▼ -7.1%on this news· ran to -32% by day 3
CareDx Reports First Quarter 2022 Results
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —
Read more →CDNACareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx Extends Artificial Intelligence Leadership to Heart Transplantation
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx to Report First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announc
Read more →CDNACareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▼ -7.1%on this newsshared move
CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation
SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting
Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMa
Read more →CDNA▼ -6.9%on this newsshared move
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx, the Leading Sponsor of UNOS Transplant Management Forum, Demonstrates the Value of Digital Solutions to Improve Pre-Transplant Patient Referral and Waitlisting Workflow
SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▼ -6%on this news
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▲ +5.7%on this newsshared move
CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▼ -5.4%on this newsshared move
CareDx Announces XenoSure and XenoMap
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▲ +7.8%on this news· ran to +26% by day 3
CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation
SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▲ +10.6%on this news· ran to +41% by day 3shared move
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNA▼ -5.7%on this news
CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx Partners with the National Kidney Foundation to Advocate for Kidney Transplant Patients
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNA▲ +12.4%on this news
CareDx Reports Fourth Quarter and Full Year 2021 Results
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -
Read more →CDNACareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNA▼ -8.3%on this newsshared move
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announce
Read more →CDNACareDx Taps into Its Patient Network to Deliver Insights on Transplant Needs
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNA▲ +6.2%on this newsshared move
CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNACareDx To Participate In Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNACareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNACareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNA▲ +18.5%on this newsshared move
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers
Read more →CDNACareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, healthcare solutions for transplant patients and caregivers – today anno
Read more →CDNA▼ -11%on this newsshared move
CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –
Read more →CDNACAREDX ALERT: Bragar Eagel & Squire, P.C. is Investigating CareDx, Inc. on Behalf of CareDx Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) on behalf of CareDx stockholders. Our investigation conc
Read more →CDNA▼ -5.1%on this news
CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, t
Read more →CDNACareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – t
Read more →CDNACareDx The Transplant Company Surpasses 80,000 Patient Milestone
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – t
Read more →CDNACAREDX INVESTIGATION: Block & Leviton Is Investigating CareDx, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating CareDx, Inc. (NASDAQ: CDNA) for potential securities law violations. Investors who have lost money in their CareDx, Inc. investment should contact the firm to learn more about how they might recover those
Read more →CDNACareDx Named One of the Fastest-Growing Companies in North America on the Deloitte Technology Fast 500™ for the Third Consecutive Year
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Enrolls First Patients in the Largest Digital Study in Transplant Using AlloCare to Assess Patient Outcomes
TEAMMATE Study to Assess Impact in 4,000 Patients Across 100 Transplant Centers SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differen
Read more →CDNACareDx To Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Acquires MedActionPlan to Directly Support Patients with Better Adherence
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Focuses on Innovation in Transplant at ASN Kidney Week
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Completes Orderly Management Transition
CareDx Completes Orderly Management Transition SOUTH SAN FRANCISCO, Calif., November 1, 2021 CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare soluti
Read more →CDNACareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx’s AlloSure Demonstrates Better Accuracy Than Current Standards of Care in Independent Kidney Transplant Study
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement
SOUTH SAN FRANCISCO, Calif. and IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for trans
Read more →CDNACareDx to Report Third Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients an
Read more →CDNACareDx Continues to Fight for Innovation in Transplantation
False Advertising Lawsuit Against Natera is Set to Go to Trial CareDx Plans to Appeal Recent Ruling in Patent Case SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, develop
Read more →CDNACareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Names Longtime Patient Advocate Art Torres to Board of Directors Torres Adds Expertise in Regenerative Medicine and Organ Procurement to the CareDx Board SOUTH SAN FRANCISCO, Calif., SEPT 15, 2021 (GLOBE NEWSWIRE)
CareDx Names Longtime Patient Advocate Art Torres to Board of Directors Torres Adds Expertise in Regenerative Medicine and Organ Procurement to the CareDx Board SOUTH SAN FRANCISCO, Calif., SEPT 15, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine
Read more →CDNACareDx to Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Showcases Leadership in Global Transplantation at ESOT 2021
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients
SOUTH SAN FRANCISCO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients, tod
Read more →CDNACareDx to Report Second Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Appoints Dr. Hannah Valantine to its Board of Directors Dr. Valantine brings deep transplant and diversity leadership expertise to the CareDx board
CareDx Appoints Dr. Hannah Valantine to its Board of Directors Dr. Valantine brings deep transplant and diversity leadership expertise to the CareDx board SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine compa
Read more →CDNACareDx CEO Reg Seeto to Present at AAKP 4th Annual Policy Summit
SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate in Raymond James 2021 Human Health Innovation Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Hosts Fireside Chat with Pro Golfer and Heart Transplant Recipient Erik Compton
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx To Acquire Transplant Hero Medication Management Application
SOUTH SAN FRANCISCO, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Presents Groundbreaking AlloSure Data at the 2021 American Transplant Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Advances Artificial Intelligence in Transplantation
SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces Strategic Minority Investment in Miromatrix
SOUTH SAN FRANCISCO, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx to Participate in Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports First Quarter 2021 Results
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Debut Multicenter Data on AlloSure Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report First Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
SOUTH SAN FRANCISCO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Present at UNOS Transplant Management Forum
SOUTH SAN FRANCISCO, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces New HLA Typing Service Offering for Research Purposes
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Enhances Leadership Team with Key Appointments
SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Supports Vir Biotechnology’s Clinical Trial Recruitment Efforts for COMET-ICE
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular
SOUTH SAN FRANCISCO, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Names Ankur Dhingra as New Chief Financial Officer
CareDx Names Ankur Dhingra as New Chief Financial Officer FRANCISCO, Calif., March 11, 2021 CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutio
Read more →CDNACareDx Expands into the Pre-Transplant Kidney Space through TX Connect
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Reports Fourth Quarter and Full Year 2020 Results
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Announces Pricing of Public Offering of Common Stock
CareDx Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., January 20, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,
Read more →CDNACareDx Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports Preliminary Fourth Quarter and Full Year 2020 Results
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Transplant Leadership Showcased at ASTS 2021
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces AlloID and Exclusive Partnership with IDbyDNA
SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of me
Read more →CDNACareDx’s AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Celebrates the Long-Awaited Passage of the Immuno Bill
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces First AlloSure Pediatrics Publication
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Receives Medicare Reimbursement Pricing for AlloSure Heart
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate at Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Joins National Kidney Foundation in Virtual Walk for Kidney Patients
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Reports Third Quarter 2020 Results
CareDx Reports Third Quarter 2020 Results SOUTH SAN FRANCISCO, CA, October 29, 2020 CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for t
Read more →CDNACareDx Showcases Leading Transplant Data at ASN 2020
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Leads in Innovation with AlloSeq Portfolio at ASHI 2020
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports Preliminary Third Quarter 2020 Revenue
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces Publication of Pivotal AlloSure Lung Data
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Receives Final Medicare Coverage Decision for AlloSure Heart
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Launches AlloCare at Virtual Transplant Festival
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Strengthens Leadership Team to Accelerate Growth
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Reports Second Quarter 2020 Results
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Participate at the Canaccord Genuity 40th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report Second Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Chairman and CEO Peter Maag to Present at Global Kidney Innovations Summit
SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx to Participate at the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and ca
Read more →CDNACareDx Presents the Latest AlloSure Data in Virtual Meetings
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx's AlloSeq Tx 17 Awarded CE Mark Approval
SOUTH SAN FRANCISCO, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and ca
Read more →CDNACareDx Brings the Transplant Patient Community Together
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap
SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports First Quarter 2020 Results
SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Engages European Lab Community in Virtual Meetings
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx and Johns Hopkins Partner on AlloSure Lung Surveillance
SOUTH SAN FRANCISCO, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) and Johns Hopkins University, announced today the launch of the ALARM (AlloSure Lung Allograft Remote Monitoring) Partnership. With the COVID 19 pandemic, there has been an emergent need
Read more →CDNACareDx Presents New Heart and Lung Transplant Data in Virtual Meetings
SOUTH SAN FRANCISCO, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report First Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Introduces AlloCell: Cell Therapy Surveillance
SOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Mobilizes 10,000 Phlebotomists for Home Blood Draws of Transplant Patients with RemoTraC
SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic South San Francisco, Calif.
CareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic South San Francisco, Calif., April 8, 2020 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, developme
Read more →CDNACareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)
SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients
SOUTH SAN FRANCISCO, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community
SOUTH SAN FRANCISCO, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients a
Read more →CDNACareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-optimization Study at CEOT
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leader in molecular diagnostics focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and car
Read more →CDNACareDx Reports Fourth Quarter and Full Year 2019 Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and
Read more →CDNACareDx to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx’s Patent Rights Upheld By Delaware Court
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Launches AiTraC Conference
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Read more →CDNACareDx’s AlloSeq cfDNA Awarded CE Mark Approval
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Leadership at ASTS Meeting
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx's False Advertising Complaint Upheld By Court
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and c
Read more →CDNACareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients
BRISBANE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx at ASN Kidney Week
BRISBANE, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Advances Patient Care with AlloSure 3.0
BRISBANE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Reports Third Quarter 2019 Results
BRISBANE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019
BRISBANE, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Participates in Transplant Roundtable with Senator Durbin
BRISBANE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Files Patent Infringement Lawsuit Against Eurofins Viracor
BRISBANE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Adds HistoMap To Testing Portfolio
BRISBANE, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication
BRISBANE, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Launches AlloSeq Tx 17 at ASHI/BANFF Meeting
BRISBANE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
BRISBANE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx launches AlloSeq cfDNA at ESOT 2019
BRISBANE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Acquires XynManagement
BRISBANE, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNAChris Cournoyer Joins CareDx Board of Directors Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio
Chris Cournoyer Joins CareDx Board of Directors Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio BRISBANE, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the
Read more →CDNACareDx Reports Second Quarter 2019 Results AlloSure momentum drives 76% second quarter revenue growth
CareDx Reports Second Quarter 2019 Results AlloSure momentum drives 76% second quarter revenue growth BRISBANE, Calif., August 1, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development and commercialization
Read more →CDNACareDx Reports Second Quarter 2019 Results
BRISBANE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACAREDX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In CareDx, Inc. To Contact The Firm
NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ:CDNA). If you invested in CareDx stock or options and would like to discuss your l
Read more →CDNACareDx to Announce Second Quarter 2019 Financial Results on August 1, 2019
BRISBANE, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
Read more →CDNACareDx Applauds White House Efforts to Reform America’s Kidney Health System
BRISBANE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds the
Read more →CDNAGrace Col n succeeds Amy Abernethy on the CareDx Board Col n brings expertise to grow patient centric innovation capabilities at CareDx
Grace Col n succeeds Amy Abernethy on the CareDx Board Col n brings expertise to grow patient centric innovation capabilities at CareDx BRISBANE, Calif., July 2, 2019 CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, an
Read more →CDNACareDx Supports Momentum in Medicare Immunosuppressive Medication Legislation
BRISBANE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds pr
Read more →CDNACareDx Announces KidneyCare and Showcases Leadership in Transplantation at ATC
BRISBANE, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will showcas
Read more →CDNACareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients
BRISBANE, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds the
Read more →CDNACareDx Reports First Quarter 2019 Results AlloSure momentum drives 85% first quarter revenue growth
CareDx Reports First Quarter 2019 Results AlloSure momentum drives 85% first quarter revenue growth BRISBANE, Calif., May 8, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinic
Read more →CDNACareDx Reports First Quarter 2019 Results
BRISBANE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financ
Read more →CDNACareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019
BRISBANE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announ
Read more →CDNACareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care
BRISBANE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced a par
Read more →CDNACareDx Agrees to Acquire OTTR Complete Transplant Management OTTR acquisition will enable EMR integrations at transplant centers and longitudinal patient data management
CareDx Agrees to Acquire OTTR Complete Transplant Management OTTR acquisition will enable EMR integrations at transplant centers and longitudinal patient data management BRISBANE, Calif., April 25, 2019 CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the
Read more →CDNACareDx to Announce First Quarter 2019 Financial Results on May 8th, 2019
BRISBANE, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, today announced that it will release financial results for the first quarter 2019 afte
Read more →CDNACareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients CareDx Files Second Lawsuit Against Natera
CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients CareDx Files Second Lawsuit Against Natera BRISBANE, Calif., April 10, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on
Read more →CDNACareDx Files Patent Infringement Lawsuit Against Natera CareDx protects innovation in transplantation by enforcing patent protection
CareDx Files Patent Infringement Lawsuit Against Natera CareDx protects innovation in transplantation by enforcing patent protection BRISBANE, Calif., March 26, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery,
Read more →CDNACareDx Reports Fourth Quarter and FY 2018 Results AlloSure launch momentum drives 88% fourth quarter revenue growth
CareDx Reports Fourth Quarter and FY 2018 Results AlloSure launch momentum drives 88% fourth quarter revenue growth BRISBANE, Calif., March 6, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercia
Read more →CDNACareDx Reports Fourth Quarter and FY 2018 Results
BRISBANE, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported fina
Read more →CDNACareDx Welcomes Initiatives from US Government to Support Transplant Care
BRISBANE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced su
Read more →CDNACareDx to Participate in the Cowen and Company 39th Annual Health Care Conference
BRISBANE, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Drives Personalized Medicine in Transplantation at CEOT
BRISBANE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced tha
Read more →CDNACareDx to Announce Fourth Quarter 2018 Financial Results on March 6th, 2019
BRISBANE, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx to Participate in BTIG 6th Annual Medical Technology, Life Science Tools and Diagnostics Conference
BRISBANE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx to Present New AlloSure Data at American Society of Transplant Surgeons Winter Symposium
BRISBANE, Calif., Jan. 09, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results
CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results BRISBANE, Calif., January 7, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiate
Read more →CDNACareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the
CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the BRISBANE, Calif., December 17, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercializat
Read more →CDNACareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer
CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer BRISBANE, Calif., November 26, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discover
Read more →CDNACareDx Announces Full Repayment of its Outstanding Debt Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet
CareDx Announces Full Repayment of its Outstanding Debt Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet BRISBANE, Calif., November 26, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and
Read more →CDNACareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
CareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase BRISBANE, Calif., November 16, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercia
Read more →CDNACareDx Reports Third Quarter Results
AlloSure launch momentum drives 74% revenue growth BRISBANE, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic sol
Read more →CDNACareDx Reports Third Quarter Results AlloSure launch momentum drives 74% revenue growth
CareDx Reports Third Quarter Results AlloSure launch momentum drives 74% revenue growth BRISBANE, Calif., November 8, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically di
Read more →CDNACareDx to Announce Third Quarter 2018 Financial Results on November 8, 2018
BRISBANE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Profiles AlloSeq Suite of NGS Products at ASHI
Expands portfolio with three new kitted transplant products launching in 2019 Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes Enables global access for laboratories to assess organ h
Read more →CDNACareDx to Participate in Upcoming Investor Conference
BRISBANE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced tha
Read more →CDNACareDx broadens HeartCare availability
BRISBANE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced th
Read more →CDNACareDx Reports Second Quarter Results AlloSure launch momentum drives 48% revenue growth
CareDx Reports Second Quarter Results AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif., August 9, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically dif
Read more →CDNACareDx Reports Second Quarter Results
AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic sol
Read more →CDNACareDx to Announce Second Quarter 2018 Financial Results on August 9, 2018
BRISBANE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNAFlatiron Health CMO/CSO Joins CareDx Board of Directors Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board
Flatiron Health CMO/CSO Joins CareDx Board of Directors Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board BRISBANE, Calif., June 28, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, dev
Read more →CDNACareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes
BRISBANE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that
Read more →CDNACareDx Promotes Living Donor Transplantation Through Employee Policy
BRISBANE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces a progressi
Read more →CDNACareDx to Hold Press Conference at American Transplant Congress
BRISBANE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will hold a press conf
Read more →CDNACareDx Reports First Quarter Results AlloSure launch momentum drives 21% revenue growth Further expands product offerings for transplant patients
CareDx Reports First Quarter Results AlloSure launch momentum drives 21% revenue growth Further expands product offerings for transplant patients BRISBANE, Calif., May 10, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discove
Read more →CDNACareDx Reports First Quarter Results
AlloSure launch momentum drives 21% revenue growth Further expands product offerings for transplant patients BRISBANE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercializatio
Read more →CDNACareDx expands NGS Transplant Product Offerings
BRISBANE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- CareDx (NASDAQ:CDNA), today announced that, as reported in its Current Report on Form 8-K filed with the Securities Exchange Commission on May 8, 2018, it entered into a License and Commercialization Agreement with Illumina, Inc.
Read more →CDNACareDx Activities at American Transplant Congress
BRISBANE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight the fir
Read more →CDNACareDx to Announce First Quarter 2018 Financial Results on May 10, 2018
BRISBANE, Calif., April 20, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Closes Debt Refinancing $15 Million Term Loan with Perceptive Advisors
CareDx Closes Debt Refinancing $15 Million Term Loan with Perceptive Advisors BRISBANE, Calif., April 18, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated
Read more →CDNACareDx Closes Debt Refinancing
BRISBANE, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Launches HeartCare for Heart Transplant Recipients
BRISBANE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the
Read more →CDNACareDx Announces Completion of Debt Conversion
BRISBANE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the
Read more →CDNACareDx Reports Fourth Quarter and FY2017 Financial Results 47 Transplantation Centers Offering AlloSure 9 Centers Enrolled in K-OAR
CareDx Reports Fourth Quarter and FY2017 Financial Results 47 Transplantation Centers Offering AlloSure 9 Centers Enrolled in K-OAR BRISBANE, Calif., March 22, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, develop
Read more →CDNACareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on March 22, 2018
BRISBANE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx to Refinance Debt with Perceptive Advisors
Balance Sheet to be Simplified with Single Term Loan BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic s
Read more →CDNACareDx to Refinance Debt with Perceptive Advisors Balance Sheet to be Simplified with Single Term Loan
CareDx to Refinance Debt with Perceptive Advisors Balance Sheet to be Simplified with Single Term Loan BRISBANE, Calif., March 1, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of c
Read more →CDNACareDx Leadership in cfDNA Highlighted at CEoT
BRISBANE, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces they will
Read more →CDNACareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 32 Transplantation Centers Offering AlloSure
CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 32 Transplantation Centers Offering AlloSure BRISBANE, Calif., January 8, 2018 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commerc
Read more →CDNACareDx Further Simplifies its Balance Sheet
CareDx Further Simplifies its Balance Sheet BRISBANE, Calif., November 15, 2017 CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant
Read more →CDNACareDx Reports Third Quarter 2017 Financial Results
CareDx Reports Third Quarter 2017 Financial Results BRISBANE, Calif., November 9, 2017 (GLOBE NEWSWIRE) CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic s
Read more →CDNACareDx Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that,
Read more →CDNACareDx to Announce Third Quarter 2017 Financial Results on November 9, 2017
BRISBANE, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
CareDx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares BRISBANE, Calif., October 10, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discover
Read more →CDNACareDx Announces Pricing of Upsized Public Offering of Common Stock
CareDx Announces Pricing of Upsized Public Offering of Calif., October 5, 2017 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions
Read more →CDNAMolDX sets AlloSure reimbursement at 2017 AlloMap level 80% of kidney transplant patients will have coverage for a validated, non-invasive test that assesses organ health by directly measuring graft injury For immediate
MolDX sets AlloSure reimbursement at 2017 AlloMap level 80% of kidney transplant patients will have coverage for a validated, non-invasive test that assesses organ health by directly measuring graft injury For immediate release: BRISBANE, Calif., September 26th, 2017 CareDx,
Read more →CDNACareDx Confirms AlloSure Will Receive Medicare Coverage Effective October 9th, 2017
BRISBANE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Reports Second Quarter 2017 Financial Results
BRISBANE, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financ
Read more →CDNACareDx Describes Extensive Analytical Validation Data on AlloSure Robustness at American Association of Clinical Chemistry Annual Meeting
BRISBANE, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, described rigorous e
Read more →CDNACareDx to Announce Second Quarter 2017 Financial Results on August 10, 2017
BRISBANE, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Restructures and Defers Certain Obligations to March 2019
BRISBANE, Calif., July 03, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported that i
Read more →CDNACareDx Reports First Quarter 2017 Financial Results
BRISBANE, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financ
Read more →CDNACareDx Activities at European Federation of Immunogenetics Congress
BRISBANE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx’
Read more →CDNACareDx Announces Receipt of Expected Letter from Nasdaq
BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that,
Read more →CDNACareDx Reports Preliminary First Quarter 2017 Financial Results
BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported prelimi
Read more →CDNACareDx to Announce First Quarter 2017 Preliminary Financial Results on May 22, 2017
BRISBANE, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that i
Read more →CDNACareDx Achieves Significant Milestone Towards CMS Coverage for AlloSure
BRISBANE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to
Read more →CDNACareDx to Present Key AlloSure Validation Data at ATC
BRISBANE, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) and collaborators will present data highlighting the AlloSure test at the American Transplantation Congress (ATC) from April 29 – May 3, 2017 in Chicago. AlloSure is the first and only noninvasive tes
Read more →CDNACareDx Appoints Michael Bell as Chief Financial Officer
BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces the appo
Read more →CDNACareDx Reports Fourth Quarter and Full Year 2016 Financial Results
BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported finan
Read more →CDNACareDx to Present New Data on AlloMap and AlloSure at ISHLT
BRISBANE, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value testing solutions for transplant recipients, announces it will onc
Read more →CDNACareDx Closes New $25 Million Debt Facility
BRISBANE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results
BRISBANE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preli
Read more →CDNACareDx to acquire SBT Resolver™ HLA Typing Products from Illumina
BRISBANE, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces that it h
Read more →CDNACareDx and Leading Transplant Clinicians to Present AlloSure DART Data During Kidney Week at the American Society of Nephrology Meeting in Chicago
BRISBANE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced it will att
Read more →CDNACareDx Reports Third Quarter 2016 Financial Results
BRISBANE, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financ
Read more →CDNACareDx to present AlloSure data at AMP in Charlotte, NC
BRISBANE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced it will pre
Read more →CDNACareDx Announces New Employment Inducement Grants
BRISBANE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 9, 2016
BRISBANE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Announces First Commercial Sale of Olerup QTYPE
BRISBANE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx’s AlloSure Featured in The Journal of Molecular Diagnostics
BRISBANE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx Launches Olerup QTYPE at ASHI
BRISBANE, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced the launch
Read more →CDNACareDx Reports Status of Form 10-Q
BRISBANE, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Reports Preliminary Second Quarter 2016 Financial Results
BRISBANE, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported prelim
Read more →CDNACareDx Presents Validation of AlloSure at AACC Conference Session on Emerging Topics in Laboratory Medicine
BRISBANE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, presented on the anal
Read more →CDNACareDx to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 10, 2016
BRISBANE, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Supports FDA Development of Next Generation Sequencing Guidelines, Offers Further Perspective on Clinical Grade Quality and Data
BRISBANE, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, commends the FDA on t
Read more →CDNACareDx Appoints Douglas Miller to Its Board of Directors
BRISBANE, Calif., July 15, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx to Host Call to Provide First Analysis of Data from DART Study
BRISBANE, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx to Present at 2016 Jefferies Healthcare Conference
BRISBANE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that P
Read more →CDNACareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology
BRISBANE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced
Read more →CDNACareDx Announces Completion of Enrollment in Multicenter Kidney Transplant Study to Validate Cell-Free DNA Technology
BRISBANE, Calif., May 27, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that t
Read more →CDNACAREDX INITIATES COMPULSORY ACQUISITION PROCEEDINGS AND ALLENEX FILES FOR DE-LISTING
CareDx, Inc ("CareDx") announced on 8 April 2016 that the company completes its public offer to the shareholders of Allenex AB (publ), ("Allenex"). After completion of the offer, CareDx holds approximately 98.3 percent of the shares of Allenex and has notified Allenex’ board o
Read more →CDNACareDx, Inc. Reports First Quarter 2016 Financial Results
BRISBANE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financi
Read more →CDNACareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap & AlloSure™ in heart transplant patients
BRISBANE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announc
Read more →CDNACareDx to Announce First Quarter 2016 Financial Results and Host Conference Call on May 6, 2016
BRISBANE, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that
Read more →CDNACareDx Completes Allenex Acquisition
BRISBANE, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today a
Read more →CDNACareDx Announces $22 Million Private Placement
BRISBANE, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) (“CareDx” or the “Company”), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for
Read more →CDNACareDx Announces the Success of Its Tender Offer for Allenex
BRISBANE, Calif., April 08, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc.’s (NASDAQ:CDNA) offer to the shareholders of Allenex AB (publ) has been accepted by shareholders holding an aggregate of 118,207,862 shares, corresponding to approximately 98.3% of the total number of shares in All
Read more →CDNACareDx Announces New Chief Commercial Officer Todd Whitson
BRISBANE, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today a
Read more →CDNACareDx Announces CFO Transition
BRISBANE, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today a
Read more →CDNACareDx, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
BRISBANE, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today r
Read more →CDNACareDx to Announce Fourth Quarter and 2015 Year-End Financial Results on March 24 and Will Present at the 28th Annual Roth Conference on March 16
BRISBANE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today a
Read more →CDNACareDx Receives Positive Coverage Decision for AlloMap From TRICARE Covering Over 9 Million Lives of U.S. Military Members and Their Families
BRISBANE, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today a
Read more →CDNACareDx Announces Revised Timeline to Its Offer to Acquire Allenex
BRISBANE, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx Announces Revised Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016
BRISBANE, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx to Participate in Upcoming Healthcare Conferences in February 2016: Leerink, BIO CEO & BTIG
BRISBANE, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients today ann
Read more →CDNACareDx and Diaxonhit Announce Completion of Technology Transfer of AlloMap Test in Europe
BRISBANE, Calif. and PARIS, Jan. 12, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients
Read more →CDNACareDx Completes Analytical Validation of AlloSure: A Next-Generation Sequencing Test Measuring Donor-Derived Cell-Free DNA in Transplant Patients
BRISBANE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients today ann
Read more →CDNACareDx Announces Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016
BRISBANE, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today an
Read more →CDNACareDx, Inc. Reports Third Quarter 2015 Financial Results
BRISBANE, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported
Read more →CDNACareDx Presents Donor-Derived Cell-Free DNA Data at the Association for Molecular Pathology and American Society of Nephrology Annual Meetings
BRISBANE, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, announc
Read more →CDNACareDx Completes Expansion of CLIA Laboratory With Next-Generation Sequencing Platform Capability
BRISBANE, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, announc
Read more →CDNACareDx to Release Third Quarter 2015 Financial Results and Host Conference Call on November 11, 2015
BRISBANE, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for transplant recipients, today
Read more →CDNACareDx CEO to Present at CMS Panel Meeting on Monday, October 19 at 8:45am ET
BRISBANE, Calif., Oct. 18, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, announ
Read more →CDNACareDx Announces New Clinical Data on AlloMap Score Variability and Service to Support Assessment of Long-Term Transplant Recipient Risk
BRISBANE, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, today
Read more →CDNACareDx Responds to Proposed CMS Clinical Laboratory Fee Schedule Changes
AlloMap and 7 Other Established Clinical Diagnostic Tests Impacted BRISBANE, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-valu
Read more →CDNACareDx Donor-Derived Cell-Free DNA Assay Selected to Support NIH-Funded CTOT-19 Clinical Trial for Transplant Patients
BRISBANE, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, today
Read more →CDNACareDx, Inc. Reports Second Quarter 2015 Financial Results
BRISBANE, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported
Read more →CDNACareDx and DNAnexus Collaborate on Cloud-Based Genomics Platform for Cell-Free DNA
BRISBANE, Calif. and MOUNTAIN VIEW Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of actionable diagnostic surveillance solutions for organ transplant recipients, and
Read more →CDNACareDx to Release Second Quarter 2015 Financial Results and Host Conference Call on August 10, 2015
BRISBANE, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for transplant recipients, today
Read more →CDNACareDx and Horizon Discovery Group Enter into a Collaboration for Development of Cell-Free DNA Reference Standards
BRISBANE, Calif. and CAMBRIDGE, United Kingdom, June 3, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for
Read more →CDNACareDx to Present at Jefferies and JMP Investor Conferences in June
BRISBANE, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx, Inc. Reports First Quarter 2015 Financial Results
Quarterly Revenue Growth of 22% Year Over Year Cell-Free DNA Technology Advances With the Release of Clinical Data and the Start of a Clinical Trial BRISBANE, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the dev
Read more →CDNACareDx Announces First Patients Enrolled in Largest-Ever Multicenter Kidney Transplant Study Using Cell-Free DNA Technology
BRISBANE, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx to Release First Quarter 2015 Financial Results and Host Conference Call on May 12, 2015
BRISBANE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announc
Read more →CDNACareDx Cell-Free DNA (cfDNA) Biomarker in Combination With AlloMap(R) Increases Accuracy of Identification of Rejection in Heart Transplant Recipients
BRISBANE, Calif. and NICE, France, April 16, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipien
Read more →CDNACareDx to Present New Data on AlloMap(R) and Cell-Free DNA (cfDNA) Biomarker in Heart Transplant Recipients at ISHLT 2015
BRISBANE, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
BRISBANE, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reporte
Read more →CDNACareDx Appoints William A. Hagstrom to Its Board of Directors
BRISBANE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx to Release Fourth Quarter 2014 Financial Results and Host Conference Call on March 17, 2015
BRISBANE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx to Present at Upcoming Investor Conferences
BRISBANE, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx Secures $20 Million Term Loan With East West Bank, Replacing Existing Credit Facility
BRISBANE, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx Announces Its Commercial European Partner Diaxonhit Has Selected Strasbourg University Hospital to Perform AlloMap(R) Testing in Europe
BRISBANE, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx Receives Positive Coverage Decision for AlloMap(R) From Two Additional Medicare Administrative Carrier Jurisdictions
BRISBANE, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx Appoints John J. Sninsky, Ph.D. as Chief Scientific Officer
BRISBANE, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx Presents HeartBrothers Foundation with a Grant to Support Heart Transplant Education and Patient Support in New England
BRISBANE, Calif., Dec. 12, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx, Inc. Reports Third Quarter 2014 Financial Results
BRISBANE, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported
Read more →CDNACareDx to Release Third Quarter 2014 Financial Results and Host Conference Call on Monday, November 10, 2014
BRISBANE, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx to Present at the BIO Investor Forum
BRISBANE, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced
Read more →CDNACareDx, Inc. Reports Second Quarter 2014 Financial Results
BRISBANE, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA) a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients today reported f
Read more →CDNACareDx to Release Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 27, 2014
BRISBANE, Calif., Aug. 14, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announce
Read more →CDNACareDx and Allegheny General Hospital Launch Research Study of Novel Test to Screen Heart Transplant Recipients for Signs of Rejection
BRISBANE, Calif. and PITTSBURGH, July 31, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA) a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients a
Read more →CDNACareDx Presents Cell-Free DNA Biomarker Results in Heart and Kidney Transplant Recipients at the World Transplant Congress
BRISBANE, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients today announced
Read more →CDNACareDx and Illumina Enter Into Supply Agreement for Next Generation Sequencing Technologies
BRISBANE, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it has
Read more →CDNACareDx Enters Into Agreement to Acquire ImmuMetrix
Transaction Strengthens CareDx's Presence in Cell-Free DNA technologies Dr. Stephen Quake to join CareDx as Scientific Advisor BRISBANE, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of cl
Read more →Competitive Position
How CDNA ranks across every disease it competes inCompetitive Position is a premium feature
See how CDNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial